The Federal Trade Commission will have more time to review Novo Holdings’ proposed $16.5 billion acquisition of Catalent.
The application was originally filed to the FTC and the Department of Justice’s antitrust division on March 4. But after “informal discussions” with the FTC, it was withdrawn and refiled by the Novo Nordisk Foundation, the parent company of Novo Holdings, on April 2 before the first application expired, according to an April 3 Catalent SEC filing.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.